Cybin Inc. to Present at Cantor Global Healthcare Conference, Showcasing Advancements in Neuropsychiatry Treatments
TL;DR
Cybin's CMO will present at the Cantor Global Healthcare Conference, offering investors early insights into the company's breakthrough mental health treatments and potential market advantages.
Cybin's CMO will discuss Phase 3 trials for CYB003 and Phase 2 studies for CYB004 during a fireside chat webcast on September 5, 2025 at 10:20 AM ET.
Cybin's innovative mental health treatments could provide effective and durable relief for millions suffering from depression and anxiety disorders worldwide.
Cybin is developing novel deuterated psychedelic compounds that have received FDA Breakthrough Therapy Designation for treating major depressive disorder and anxiety.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin's investor relations website at https://ibn.fm/N8ObB.
The company is developing next-generation treatment options for mental healthcare, focusing on addressing the large unmet need for people suffering from mental health conditions. Cybin's current pipeline includes CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder. This treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies.
Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of neuropsychiatry innovation. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland, demonstrating its global commitment to mental health treatment advancement.
The participation in the Cantor Global Healthcare Conference provides an opportunity for Cybin to showcase its promising class-leading data and discuss how the company is working to change the mental health treatment landscape. The development of novel drugs that provide effective and durable results for patients represents a significant advancement in a field where traditional treatments often fall short. Investors and healthcare professionals can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.
This conference appearance comes at a critical time for mental healthcare innovation, as the global mental health crisis continues to grow and the need for more effective treatments becomes increasingly urgent. Cybin's approach to developing next-generation neuropsychiatry treatments could potentially transform how mental health conditions are managed worldwide, offering new hope for patients who have not responded to conventional therapies.
Curated from InvestorBrandNetwork (IBN)
